Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study
Top Cited Papers
Open Access
- 1 April 2002
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 40 (4) , 1298-1302
- https://doi.org/10.1128/jcm.40.4.1298-1302.2002
Abstract
Bloodstream infections due to Candida species cause significant morbidity and mortality. Surveillance for candidemia is necessary to detect trends in species distribution and antifungal resistance. We performed prospective surveillance for candidemia at 16 hospitals in the State of Iowa from 1 July 1998 through 30 June 2001. Using U.S. Census Bureau and Iowa Hospital Association data to estimate a population denominator, we calculated the annual incidence of candidemia in Iowa to be 6.0 per 100,000 of population. Candida albicans was the most common species detected, but 43% of candidemias were due to species other than C. albicans. Overall, only 3% of Candida species were resistant to fluconazole. However, Candida glabrata was the most commonly isolated species other than C. albicans and demonstrated some resistance to azoles (fluconazole MIC at which 90% of the isolates tested are inhibited, 32 μg/ml; 10% resistant, 10% susceptible dose dependent). C. glabrata was more commonly isolated from older patients (P = 0.02) and caused over 25% of candidemias among persons 65 years of age or older. The investigational triazoles posaconazole, ravuconazole, and voriconazole had excellent in vitro activity overall against Candida species. C. albicans is the most important cause of candidemia and remains highly susceptible to available antifungal agents. However, C. glabrata has emerged as an important and potentially antifungal resistant cause of candidemia, particularly among the elderly.Keywords
This publication has 22 references indexed in Scilit:
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Fungal Infections in Older AdultsClinical Infectious Diseases, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Risk factors for candidemia in Neonatal Intensive Care Unit patientsThe Pediatric Infectious Disease Journal, 2000
- Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 2000
- National Epidemiology of Mycoses Survey (NEMIS): Variations in Rates of Bloodstream Infections Due to Candida Species in Seven Surgical Intensive Care Units and Six Neonatal Intensive Care UnitsClinical Infectious Diseases, 1999
- Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year AnalysisClinical Infectious Diseases, 1999
- Antifungal resistance in non- albicans Candida speciesDrug Resistance Updates, 1999
- Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida InfectionsClinical Infectious Diseases, 1997
- Hospital-acquired candidemia. The attributable mortality and excess length of stayArchives of internal medicine (1960), 1988